

Linda Wittkop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8331465/publications.pdf>

Version: 2024-02-01

114
papers

2,473
citations

236833

25
h-index

233338

45
g-index

117
all docs

117
docs citations

117
times ranked

4171
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 163-177.	2.8	120
2	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. <i>JHEP Reports</i> , 2022, 4, 100481.	2.6	3
3	Tobacco use in people living with HIV: The need for complementary descriptive data to see beyond the smoke screen. <i>International Journal of Drug Policy</i> , 2022, 102, 103616.	1.6	1
4	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. <i>Journal of Cannabis Research</i> , 2022, 4, .	1.5	1
5	Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. <i>Journal of Hepatology</i> , 2021, 74, 37-47.	1.8	21
6	Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, e215-e223.	2.9	6
7	Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV-HCV co-infected individuals. <i>Clinical and Experimental Immunology</i> , 2021, 204, 107-124.	1.1	1
8	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1147-1156.	2.0	6
9	HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). <i>AIDS and Behavior</i> , 2021, 25, 4141-4153.	1.4	8
10	Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection. <i>Journal of Virology</i> , 2021, 95, e0001621.	1.5	9
11	A French cohort for assessing COVID-19 vaccine responses in specific populations. <i>Nature Medicine</i> , 2021, 27, 1319-1321.	15.2	14
12	Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfecting participants. <i>HIV Medicine</i> , 2021, 22, 791-804.	1.0	1
13	Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis. <i>HIV Medicine</i> , 2021, 22, 924-935.	1.0	2
14	Post-HCV cure self-reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH). <i>Journal of Viral Hepatitis</i> , 2021, 28, 1665-1667.	1.0	2
15	Statin use and risk of severe bacterial infection in a population living with HIV: prospective cohort study of the ANRS CO3 Aquitaine Cohort 2000-2018. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1301-1307.	2.8	1
16	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021, 73, 50-59.	2.9	18
17	Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). <i>Hepatology</i> , 2020, 71, 1182-1197.	3.6	8
18	HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort). <i>AIDS and Behavior</i> , 2020, 24, 1069-1084.	1.4	12

#	ARTICLE	IF	CITATIONS
19	Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS CO13 HEPAVIH). <i>Journal of Hepatology</i> , 2020, 72, 588-591.	1.8	7
20	Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). <i>Trials</i> , 2020, 21, 846.	0.7	21
21	Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort's QuAliv ancillary study. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 220.	1.0	6
22	Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH). <i>Journal of Viral Hepatitis</i> , 2020, 27, 1462-1472.	1.0	6
23	Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH). <i>Nutrients</i> , 2020, 12, 2532.	1.7	7
24	Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis. <i>Journal of Clinical Apheresis</i> , 2020, 35, 281-289.	0.7	7
25	Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz549.	0.4	3
26	Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort. <i>Clinical Infectious Diseases</i> , 2020, 71, 2536-2538.	2.9	2
27	Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection. <i>Aids</i> , 2020, 34, 953-954.	1.0	5
28	Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. <i>Liver International</i> , 2019, 39, 136-146.	1.9	9
29	Increased liver stiffness is associated with mortality in HIV/HCV coinfecting subjects: The French nationwide ANRS CO13 HEPAVIH cohort study. <i>PLoS ONE</i> , 2019, 14, e0211286.	1.1	8
30	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1224-1228.	1.0	15
31	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	1.6	75
32	No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH) <i>Tj ETQq0 0 0 r gBT /Overlock 10 TF</i>	0.8	2
33	Elevated fatty liver index as a risk factor for all-cause mortality in HIV-HCV co-infected patients. <i>European Journal of Public Health</i> , 2019, 29, .	0.1	0
34	Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 461-466.	0.9	0
35	Sleep disturbances in HIV-HCV coinfecting patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort). <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1508-1517.	0.8	9
36	Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1387-1396.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-stage Liver Disease as Compared to HCV Mono-infected Patients. <i>Hepatology</i> , 2019, 70, 939-954.	3.6	28
38	Web-Based Module for the Collection of Electronic Patient-Reported Outcomes in People Living With HIV in Nouvelle Aquitaine, France: Usability Evaluation. <i>JMIR Formative Research</i> , 2019, 3, e15013.	0.7	2
39	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	2.9	105
40	Gender, Alcohol Use, and Fibrosis in Human Immunodeficiency Virus/Hepatitis C Virus Co-infected Individuals. <i>Clinical Infectious Diseases</i> , 2018, 66, 983-984.	2.9	1
41	The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , 2018, 68, 845-847.	1.8	9
42	Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance. <i>Journal of Viral Hepatitis</i> , 2018, 25, 314-315.	1.0	2
43	Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort. <i>PLoS ONE</i> , 2018, 13, e0208657.	1.1	3
44	Lasso regularization for left-censored Gaussian outcome and high-dimensional predictors. <i>BMC Medical Research Methodology</i> , 2018, 18, 159.	1.4	6
45	Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. <i>Journal of the International AIDS Society</i> , 2018, 21, e25200.	1.2	6
46	Wine Consumption and Lower Risk of Advanced Liver Fibrosis: A True Effect or Unmeasured Confounding? A Longitudinal Analysis (ANRS CO13 HEPAVIH Cohort). <i>American Journal of Gastroenterology</i> , 2018, 113, 1729-1732.	0.2	1
47	Multimorbidity, age-related comorbidities and mortality. <i>Aids</i> , 2018, 32, 1651-1660.	1.0	57
48	Protective effect of cannabis and coffee consumption on HCV-related mortality in French HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort). <i>Journal of Hepatology</i> , 2018, 68, S142-S143.	1.8	5
49	Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. <i>PLoS ONE</i> , 2018, 13, e0199874.	1.1	3
50	Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS CO-13 HEPAVIH Cohort). <i>Nutrients</i> , 2018, 10, 705.	1.7	18
51	Impact of elevated coffee intake on the risk of advanced liver fibrosis in HIV-HCV co-infected patients of the French ANRS CO13 HEPAVIH cohort: a sex-based analysis. <i>Journal of Hepatology</i> , 2018, 68, S175-S176.	1.8	0
52	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+. <i>Aids</i> , 2018, 32, 1361-1367.	1.0	14
53	Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. <i>HIV Medicine</i> , 2018, 19, 42-48.	1.0	8
54	Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13 HEPAVIH). <i>Journal of Viral Hepatitis</i> , 2018, 25, 171-179.	1.0	23

#	ARTICLE	IF	CITATIONS
55	Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfecting patients. <i>World Journal of Hepatology</i> , 2018, 10, 856-866.	0.8	10
56	No significant effect of cannabis use on the count and percentage of circulating CD4 T cells in HIV/HCV co-infected patients (ANRS CO13-HEPAVIH French cohort). <i>Drug and Alcohol Review</i> , 2017, 36, 227-238.	1.1	18
57	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort. <i>Journal of Hepatology</i> , 2017, 67, 23-31.	1.8	45
58	Activation, senescence and inflammation markers in HIV patients. <i>Aids</i> , 2017, 31, 1119-1128.	1.0	6
59	Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , 2017, 67, 1157-1167.	1.8	25
60	The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1054-1060.	1.9	66
61	Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. <i>Aids</i> , 2017, 31, 2355-2365.	1.0	4
62	Rapid Adenovirus typing method for species identification. <i>Journal of Virological Methods</i> , 2017, 249, 156-160.	1.0	2
63	HIV/HCV-coinfecting cirrhotic patients are no longer at higher risk of hepatocellular carcinoma or end-stage liver disease as compared to HCV-monoinfecting patients (ANRS CO12 CirVir and ANRS CO13) Tj ETQq1 1.0.784314 rgBT / O	1.0	2
64	Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe. <i>Aids</i> , 2017, 31, 253-262.	1.0	19
65	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	2.9	75
66	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. <i>Aids</i> , 2017, 31, 835-846.	1.0	14
67	Characterization of Biomarkers of Tumorigenic and Chemo-resistant Cancer Stem Cells in Human Gastric Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 1586-1597.	3.2	117
68	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	1.3	17
69	Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients. <i>PLoS ONE</i> , 2017, 12, e0169164.	1.1	5
70	Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH). <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 786-791.	0.8	4
71	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	1.1	30
72	Short article: Fatigue in the long term after HCV treatment in HIV/HCV-coinfecting patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1003-1007.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	2.9	20
74	End-Stage Liver Disease in HIV Infection: An Avoidable Burden?. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw537.	2.9	1
75	Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 521-526.	1.5	24
76	Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project. <i>BMC Infectious Diseases</i> , 2016, 16, 654.	1.3	7
77	All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus – coinfecting Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13 – HEPAVIH Cohort. <i>Clinical Infectious Diseases</i> , 2016, 63, 763-770.	2.9	52
78	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
79	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062.	1.3	22
80	P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER. <i>Journal of Hepatology</i> , 2015, 62, S630-S631.	1.8	0
81	P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV mono-infection: Data from the French cohort – ANRS CO22 hepather. <i>Journal of Hepatology</i> , 2015, 62, S488-S489.	1.8	1
82	Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients. <i>Aids</i> , 2015, 29, 2099-2108.	1.0	47
83	Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada. <i>Aids</i> , 2015, 30, 1.	1.0	6
84	Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1 – coinfecting patients. <i>Liver International</i> , 2015, 35, 2090-2099.	1.9	10
85	Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfecting patients. <i>Aids</i> , 2015, 29, 1821-1830.	1.0	37
86	Mortality in migrants living with HIV in western Europe (1997 – 2013): a collaborative cohort study. <i>Lancet HIV</i> , 2015, 2, e540-e549.	2.1	19
87	LP20 : Safety and efficacy of all-oral daa regimens in HIV-HCV coinfecting cirrhotic patients from the prospective ANRS CO13 - HEPAVIH cohort. <i>Journal of Hepatology</i> , 2015, 62, S273-S274.	1.8	3
88	LP23 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HIV – HCV co-infection: interim analysis of a French multicenter compassionate use program. <i>Journal of Hepatology</i> , 2015, 62, S275.	1.8	2
89	P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER. <i>Journal of Hepatology</i> , 2015, 62, S631-S632.	1.8	8
90	HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. <i>Journal of Clinical Virology</i> , 2015, 73, 32-35.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015, 20, .	3.9	70
92	T-cell activation discriminates subclasses of symptomatic primary humoral immunodeficiency diseases in adults. <i>BMC Immunology</i> , 2014, 15, 13.	0.9	6
93	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. <i>Lancet HIV</i> , 2014, 1, e119-e126.	2.1	32
94	Effect of Cytomegalovirus-Induced Immune Response, Self Antigen-Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1-Infected Patients: The ANRS CO3 Aquitaine Cohort. <i>Journal of Infectious Diseases</i> , 2013, 207, 622-627.	1.9	61
95	Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	1.9	7
96	Dynamic and Rapid Changes in Viral Quasispecies by Udfs in Chronic Hepatitis C Patients Receiving Telaprevir-Based Therapy. <i>Antiviral Therapy</i> , 2013, 18, 723-727.	0.6	12
97	CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. <i>PLoS Medicine</i> , 2012, 9, e1001194.	3.9	145
98	56 DYNAMICS OF HCV QUASISPECIES DURING TELAPREVIR TREATMENT DISSECTED USING ULTRA-DEEP PYROSEQUENCING: TREATMENT FAILURE IN 100% OF GENOTYPE 1A PATIENTS. <i>Journal of Hepatology</i> , 2012, 56, S25.	1.8	1
99	Mathematical analysis of a HIV model with quadratic logistic growth term. <i>Discrete and Continuous Dynamical Systems - Series B</i> , 2012, 17, 2359-2385.	0.5	5
100	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , 2011, 11, 363-371.	4.6	345
101	Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. <i>Digestive and Liver Disease</i> , 2011, 43, 975-983.	0.4	28
102	708 OVERLAPPING STRUCTURE OF HBV GENOME AND IMMUNE SELECTING PRESSURE ARE THE MAIN DRIVING FORCES FOR HBV EVOLUTION. <i>Journal of Hepatology</i> , 2011, 54, S284-S285.	1.8	0
103	Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. <i>HIV Medicine</i> , 2011, 12, 506-509.	1.0	27
104	Red scrotum syndrome. <i>Journal of Dermatological Case Reports</i> , 2011, 5, 38-41.	1.1	24
105	Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation. <i>Cellular Microbiology</i> , 2010, 12, 962-975.	1.1	38
106	Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in vitro infected cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 434-437.	1.3	22
107	HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1262-1269.	1.3	63
108	Analysis of RT Sequences of Subtype C HIV-Type 1 Isolates from Indian Patients at Failure of a First-Line Treatment According to Clinical and/or Immunological WHO Guidelines. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 343-350.	0.5	19

#	ARTICLE	IF	CITATIONS
109	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. <i>Clinical Trials</i> , 2010, 7, 19-35.	0.7	33
110	1025 THE GENETIC BARRIER MODULATES THE IMMUNE ESCAPE POTENTIAL OF HBV GENOTYPES. <i>Journal of Hepatology</i> , 2010, 52, S396-S397.	1.8	0
111	Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1251-1255.	1.3	33
112	Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy. <i>BMC Medical Research Methodology</i> , 2008, 8, 68.	1.4	4
113	Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). <i>Antiviral Therapy</i> , 2008, 13, 271-9.	0.6	9
114	Virological Response to Darunavir/Ritonavir-Based Regimens in Antiretroviral-Experienced Patients (PREDIZISTA Study). <i>Antiviral Therapy</i> , 2008, 13, 271-280.	0.6	25